This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
by Zacks Equity Research
BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.
BMYPositive Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure
by Zacks Equity Research
AstraZeneca tops Q2 earnings and revenue estimates as strong demand for oncology and rare disease drugs helps offset growing generic competition across key products.
AZNNegative Net Change SNYNegative Net Change MRKNegative Net Change AMGNNo Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
by Sundeep Ganoria
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
BIIBNegative Net Change INSMNegative Net Change AGIONegative Net Change ACADPositive Net Change HRMYNo Net Change
biotechs earnings
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
by Kanishka Das
Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.
IMCRPositive Net Change BMYPositive Net Change MRKNegative Net Change
biotechs
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
by Kanishka Das
Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, infectious disease and autoimmune markets.
IMCRPositive Net Change BMYPositive Net Change ADAPYPositive Net Change
biotechs
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead
by Kanishka Das
IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to test its next expansion opportunity.
IMCRPositive Net Change BMYPositive Net Change MRKNegative Net Change
biotechs
Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?
by Zacks Equity Research
VRTX heads into its Q2 earnings release with Trikafta, Alyftrek, Casgevy and Journavx in focus as investors watch product sales and updates on ongoing pipeline studies.
VRTXNegative Net Change PFENegative Net Change ACADPositive Net Change CRSPPositive Net Change
biotechs
Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
NBIX heads into Q2 results with a focus on Ingrezza sales, Crenessity growth and pipeline updates as investors watch key commercial and clinical progress.
NBIXPositive Net Change AGIONegative Net Change ACADPositive Net Change HRMYNo Net Change
biotechs
EU Clears AZN's Etcamah Combo for First-Line ER-Positive Breast Cancer
by Zacks Equity Research
AstraZeneca secures EU approval for Etcamah in combination with a CDK4/6 inhibitor for first-line treatment of advanced ER-positive breast cancer patients.
AZNNegative Net Change LQDANegative Net Change KNSANegative Net Change HRMYNo Net Change
biotechs
Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?
by Ekta Bagri
Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.
UTHRPositive Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals